Advertisement

 

 

The overlap of sleep disturbance and depression in primary care patients treated with buprenorphine.

The overlap of sleep disturbance and depression in primary care patients treated with buprenorphine.
Author Information (click to view)

Garnaat SL, Weisberg RB, Uebelacker LA, Herman DS, Bailey GL, Anderson BJ, Sharkey KM, Stein MD,


Garnaat SL, Weisberg RB, Uebelacker LA, Herman DS, Bailey GL, Anderson BJ, Sharkey KM, Stein MD, (click to view)

Garnaat SL, Weisberg RB, Uebelacker LA, Herman DS, Bailey GL, Anderson BJ, Sharkey KM, Stein MD,

Advertisement

Substance abuse 2017 09 13() 0 doi 10.1080/08897077.2017.1361498
Abstract
BACKGROUND
Sleep disturbance is common among patients receiving long-term opioid therapies, such as methadone maintenance. However, little is known about sleep disturbances in patients receiving medication treatment with buprenorphine. We sought to determine the frequency of subjective sleep disturbance in a sample of patients receiving medication treatment and to examine clinical factors related to sleep disturbance.

METHOD
Participants were 328 persons receiving buprenorphine at three primary care sites. We assessed sleep difficulty using two questions adapted from the PHQ-9 item assessing sleep. Depressive symptoms were assessed using the CESD-10 and PHQ-2. In addition, information was gathered on participant demographics and treatment characteristics. We compared demographics, buprenorphine treatment history, and depressive symptoms for those with and without self-reported sleep difficulty. We used logistic regression to estimate the adjusted association of sleep disturbance with these correlates.

RESULTS
Seventy-one percent of persons receiving medication treatment with burprenophine in our study reported sleep difficulty. Persons reporting sleep disturbance reported shorter time in buprenorphine treatment and more depressed mood compared to those without sleep difficulty (p<.01). Men were significantly less likely to report disturbed sleep than women (OR = 0.57, 95%CI 0.33; 0.98). Sleep disturbance was not associated significantly with age, ethnicity, educational attainment, or buprenorphine dose. CONCLUSIONS
Sleep disturbance is common in patients receiving medication treatment with burphrenorphine and is associated with more depressive symptoms as well as a shorter duration of medication treatment. Future research, using subjective and objective sleep measures, is warranted to understand whether sleep disturbance is mitigated by longer buprenorphine treatment and whether difficulty sleeping predicts buprenorphine discontinuation among patients seeking treatment for opioid dependence.

Submit a Comment

Your email address will not be published. Required fields are marked *

six + 17 =

[ HIDE/SHOW ]